PROK Share Price Performance
US$1.87
0.28 (17.61%)
Price US$1.87
Share Pricen/a
ProKidney Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
PROK Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
ProKidney Corp. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.50
- 100.00%
- -9,547.45%
- 0%
About PROK
- Founded
- 2015
- Employees
- 204
- CEO
- WebsiteView website
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
